SP Group

Strong Q3 2026 lifts lower end of guidance



Rasmus Køjborg
+45 61 20 30 78
Rasmus@hcandersencapital.dk




Jacob Frehr
+45 42 42 55 85
Jacob@hcandersencapital.dk

Corporate customer
Full disclaimer on back page
25.11.2026 16:00

HC ANDERSEN CAPITAL

Key Financials and Valuation

Share price



YTD	21.2%	1 year:	52.3%
1 month:	-8.0%	3 years:	122.0%

Note: We apply closing price from November 24, 2026. Source: S&P Capital IQ.

Financials

DKKm	2024	2025	2026E	2027E
Revenue	2,922	2,948	3,895	4,311
Revenue growth	12.1%	0.9%	32.1%	10.7%
EBITDA	589	595	790	905
EBITDA-%	20.1%	20.2%	20.3%	21.0%
Net income	262	267	386	471
Net debt	821	1,460	1,497	1,497
Market value	3,709	4,098	4,885	4,885
EV/Sales (x)	1.6	1.9	1.6	1.5
EV/EBITDA (x)	7.7	9.3	8.1	7.1
EV/EBIT (x)	11.7	14.0	11.6	9.8
P/E (x)	14.1	15.3	12.7	10.4

Note: Data is from S&P Capital IQ. 2026E consensus implies 32.1% revenue growth, above the guided 26-30% range.

Outlook and ambitions

DKKm	2026E	2030E
Revenue	3.70-3.85 bn	4.5 bn
Revenue growth	26-30%	6-9% CAGR
EBITDA	705-805	950
EBITDA-margin	19-21%	20-22%
EBT	410-500	600
EBT-margin	11-13%	12-14%

Note: Numbers are SP Group's own guidance and targets. Revenue rounded to nearest DKK 50m, EBITDA and EBT rounded to nearest DKK 5m.

Valuation Perspectives


SP Group trades at 8.1x EV/EBITDA (2026E), a 4% premium to the peer median of 7.8x but retains a notable discount on EV/EBIT of 11.6x vs. 17.0x for peers. Question marks regarding the integration of Ide-Pro and OGM remain, however, a record first nine months of 2026 should ease concerns of the volatile earnings seen in 2025.

SP Group's growth profile stands out with a 10-year revenue CAGR of 8.4% and EBITDA margin expansion from 12.4% (2015) to 19.9% in 9M 2026, with an LTM EBIT margin of 14.1% against a peer median of 3.7%. The expansion reflects a rising share of own products, more of the value chain and automation. Despite the Ide-Pro and OGM acquisitions SP Group continued its shareholder returns with a DKK 4.0/share dividend and a buyback raised to DKK 80m.

Catalysts for further re-rating include sustaining momentum into 2027 and showing that margins can be maintained despite the shift towards subsupplier projects. Demonstrating cross sales and synergies from Ide-Pro and OGM can also be key. The 2030 ambitions look set to be revisited. Set in March 2025 on 6-9% annual growth including only minor acquisitions, and without deals of the size of Ide-Pro and OGM, the DKK 4.5bn revenue target is within reach in 2028 on consensus, and an update would give the market a new reference point.

Raw-material inflation and geopolitical uncertainty may pressure valuation. The YTD total return of 21.2% vs. a peer median of 6.4% has closed the EV/EBITDA discount seen in the spring, and further expansion likely requires growth to pick up in 2027 after the 0-14% guidance implies for Q4.

Valuation multiples



Investment Case – Moulded plastic compounder in a fragmented market

Key Investment Reasons

- SP Group combines organic growth with acquisitions that widen its portfolio and geographic reach. Own brands still support EBITDA margin growth, despite slipping to 23% of revenue in 9M 2026 from 27% in FY25 (30% FY24).
- Buy-and-build has driven a 10-year revenue CAGR of 8.4%, and the discipline on acquisition multiples has been value creating. OGM Moulding follows Ide-Pro at roughly 4.8x EV/EBITDA, adding UK production and cleanroom capacity, with leverage at 2.0x in Q3 and still supporting shareholder returns.
- SP Group's largest segments in 9M 2026 were Healthcare (35%), Cleantech (29%) and Foodtech (14%), benefit from ageing populations, green transition, and food insecurity, reducing cyclicality.

Key Investment Risks

- SP Group's ten largest customers accounted for 49% of revenue in 2025 and the largest for 11.4%, leaving some concentration risk, although concentration has generally been declining.
- Ide-Pro is significantly larger than previous acquisitions, which may challenge both integration and the realisation of expected synergies. At 7.6x EV/EBITDA it is also priced well above the historical sub-5x, raising the synergies needed to reach a similar IRR. OGM adds a second integration.
- The Middle East conflict has lifted raw material and energy prices. SP Group can largely pass this on and has shifted much of its gas to green energy, but a growth shock or renewed inflation could still pressure margins.

Company description: SP Group is a Danish-based manufacturing company producing advanced plastic and composite components and performs coatings on plastic and metal products. It produces products under its own trademarks and products for other firms as a sub-supplier. SP Group operates globally, with 74% of global sales in Europe (27% of which in DK). Additionally, the group supplies a variety of industries, with healthcare, cleantech, and food-related industries being the three largest, together 80% of sales in 2025.

Investment case: SP Group's moulded plastics segment experiences structural support as customers seek cheap, lightweight, and less carbon-intensive alternatives to metal/glass components. The company maintains its 'buy and build' strategy, based on organic and acquisitive growth, which has supported revenue and EBT CAGR of 8.4% and 15.5%, respectively, from 2015-2025. Ide-Pro brings in-house toolmaking, prototyping, and an expanded engineering platform in India, with synergies of DKK 20-25m expected in full from 2027. In August, SP Group added OGM Moulding for GBP 18.0m fixed plus up to GBP 6.0m in earn-out, at 4.8x EV/EBITDA, giving two UK plants and a Box-Build capability.

After a mixed 2025 with a US-driven trade war, SP Group delivered a record first nine months. 9M 2026 revenue rose 36.1% to DKK 2,888m, EBITDA 38.0% to DKK 576m at a 19.9% margin, and EBT 52.6% to DKK 350m, above all of 2025. On 17 November, the lower end of revenue growth guidance was lifted to 26-30%, while the 19-21% EBITDA and 11-13% EBT margin ranges were left unchanged.

Q3 delivered revenue growth of 43.2%, of which 23.9% organic, against a soft Q3 2025 as projects slid into Q4 2025. Management says this shift weighs on organic growth in Q4, where guidance implies 0-14% growth. All four product groups grew: Other 98%, Cleantech 40%, Healthcare 31% and Foodtech 28%. Subsupplier projects grew 41.8% against 20.3% for own products in 9M, and the Q3 EBITDA margin eased to 19.1% (19.3%). NIBD rose to DKK 1,497m and 2.0x EBITDA, within the 1.0-3.5x policy range.

SP Group now trades at a premium to peers on EV/EBITDA, but at discounts of 32% on EV/EBIT and 41% on P/E, having returned 21.2% year to date against a peer median of 6.4%. The premium turns into a discount further down the income statement, as SP Group converts more of its EBITDA into operating profit (EBIT) than peers do. As guidance implies 0-14% growth in Q4, the focus may turn to whether growth picks up again in 2027 and whether margins hold.

The 2030 ambitions look set to be revisited. Management confirmed on the H1 webcast that the March 2025 targets of approximately DKK 4.5bn revenue, DKK 950m EBITDA and DKK 600m EBT were set on assumptions of 6-9% annual growth including minor acquisitions and did not assume deals of the size of Ide-Pro and OGM. On a rolling 12-month basis revenue is DKK 3.71bn and consensus points to DKK 4.31bn in 2027, leaving the revenue ambition attainable in 2028, two years early. The EBITDA ambition is as close, with consensus at DKK 905m in 2027 against DKK 950m.

Peer Group – Plastics manufacturing peers

Our SP Group peer group comprises companies engaged in the manufacture of plastic and composite products, with multiple product segments and international operations.

SP Group produces advanced plastic and composite components and performs coatings on plastic and metal products, operating globally with 74% of sales in Europe. The company supplies a variety of industries, with Healthcare (35%), Cleantech (29%) and Foodtech (14%), as its three largest segments in 9M 2026, and pursues a buy-and-build strategy combining organic growth with acquisitive consolidation in a fragmented market.

Plastic manufacturing peers: Polytec Holding AG (Austrian manufacturer of plastic components for automotive, aerospace, and industrial sectors), Nolato AB (Swedish manufacturer of polymer-based products across medical, industrial, and telecom segments), Gerresheimer AG (German manufacturer of specialty glass and plastic products primarily for pharmaceutical and medical industries), and BEWI ASA (Norwegian manufacturer of particle foam products and insulated packaging solutions for construction, packaging, and automotive sectors).

Nolato and Gerresheimer are the most directly comparable given their multi-segment polymer/plastics focus and healthcare exposure, while Polytec is more automotive-oriented and BEWI is focused on foam-based insulation and packaging solutions. There is no identical peer to SP Group, but the shared characteristics of plastics manufacturing, multiple product segments, and international operations make the comparisons appropriate.


Peer group


Company	Price (local)	Total return YTD	Market cap (EURm)	EV (EURm)	EV/EBITDA		EV/EBIT		P/E		EBIT margin (%)	
					2025	2026E	2025	2026E	2025	2026E	3-yr avg	LTM
Polytec Holding AG	EUR 3.7	17.7%	82	132	3.8	3.4	13.6	13.2	27.5	24.1	0.7%	2.8%
Gerresheimer AG	EUR 32	16.1%	1,106	3,289	7.8	8.2	20.4	28.1	40.8	16.9	8.2%	1.6%
Nolato AB (publ)	SEK 52.6	-12.0%	1,262	1,422	11.1	10.8	17.5	15.7	21.2	18.5	9.0%	10.0%
BEWI ASA	NOK 18.1	-3.3%	399	807	11.3	7.3	105.4	18.3	16.9	160.3	1.3%	4.5%
Median		**6.4%**	**752**	**1,114**	**9.5**	**7.8**	**18.9**	**17.0**	**24.3**	**21.3**	**4.8%**	**3.7%**
SP Group A/S	**DKK 416**	**21.2%**	**654**	**854**	**9.3**	**8.1**	**14.0**	**11.6**	**15.3**	**12.7**	**11.9%**	**14.1%**
Premium (+) / Discount (-) to peers					*-1.4%*	*4.1%*	*-26.2%*	*-32.0%*	*-37.0%*	*-40.6%*		


Note: Data from 24/11/2026


Source: S&P Capital IQ

Valuation vs. Peers












Valuation vs. Historical







HC Andersen Capital

HC Andersen Capital digitalizes and democratizes the relationship between investors and listed companies.

Through digital investor events, commissioned research, advisory services, and related IR services, we engage investors with information and access to the companies' management. We want equal access to information for all investors, private as well as institutional.

We believe that all information should be equally accessible for all investors, and that improving the symmetry of information between companies and all investors strengthens company-investor relationships and trust in the financial markets.

Our team of analysts has many years of experience in the financial markets, previously with leading Nordic institutions.

HC Andersen Capital is based in Copenhagen, Denmark, and operates in the Nordics. HC Andersen Capital works closely in partnership with the leading Finnish-based equity research company, Inderes Oyj.

HC Andersen Capital

Bredgade 23B 2. sal
1260 København K, Denmark
CVR: 41474793

All research available at **inderes.dk**

Equity research team



Michael Friis
Head of Equities



Rasmus Køjborg
Head of Research



Victor Skriver
Equity Analyst Assistant



Jacob Frehr
Equity Analyst Assistant



William Jørck
Equity Analyst Assistant



Nikolaj Pedersen
Equity Analyst Assistant

Disclaimer

This research report (the "Investment Case") has been commissioned and paid for by the company that is the subject of this report. HC Andersen Capital has received payment from the covered company for the preparation and distribution of this Investment Case.

The information presented in HC Andersen Capital reports is obtained from several different public sources that HC Andersen Capital considers to be reliable. HC Andersen Capital aims to use reliable and comprehensive information, but HC Andersen Capital does not guarantee the accuracy of the presented information. Any opinions, estimates and forecasts represent the views of the authors. HC Andersen Capital is not responsible for the content or accuracy of the presented information. HC Andersen Capital and its employees are also not responsible for the financial outcomes of investment decisions made based on the reports or any direct or indirect damage caused by the use of the information. The information used in producing the reports may change quickly. HC Andersen Capital makes no commitment to announcing any potential changes to the presented information and opinions.

The reports produced by HC Andersen Capital are intended for informational use only. The reports should not be construed as offers or advice to buy, sell or subscribe investment products. This report does not contain and should not be interpreted as containing: (i) price targets or fair value estimates for the company's securities; (ii) buy, sell, hold, accumulate, reduce or any equivalent investment recommendations; or (iii) personalised investment advice. Customers should also understand that past performance is not a guarantee of future results. When making investment decisions, customers must base their decisions on their own research and their estimates of the factors that influence the value of the investment and take into account their objectives and financial position and use advisors as necessary. Customers are responsible for their investment decisions and their financial outcomes.

Reports produced by HC Andersen Capital may not be edited, copied or made available to others in their entirety, or in part, without HC Andersen Capital's written consent. No part of this report, or the report as a whole, shall be transferred or shared in any form to the United States, Canada or Japan or the citizens of the aforementioned countries. The legislation of other countries may also lay down restrictions pertaining to the distribution of the information contained in this report. Any individuals who may be subject to such restrictions must take said restrictions into account.

The analysts who produce HC Andersen Capital's research cannot have shareholdings in the companies they cover. The remuneration of the analysts who produce the analysis is not directly or indirectly linked to the content, conclusions, or any views expressed in the reports.

HC Andersen Capital or its partners whose customer relationships may have a financial impact on HC Andersen Capital may, in their business operations, seek assignments with various issuers with respect to services provided by HC Andersen Capital or its partners. Thus, HC Andersen Capital may be in a direct or indirect contractual relationship with an issuer that is the subject of research activities. HC Andersen Capital and its partners may provide different services to issuers.

More information about research disclaimers can be found at inderes.dk/research-disclaimer.

This research is produced and distributed in accordance with the EU Market Abuse Regulation (MAR) (Regulation EU 596/2014) and Commission Delegated Regulation (EU) 2016/958. HC Andersen Capital ApS is based in Denmark.


Connecting investors
and listed companies.
HC ANDERSEN
CAPITAL